2017
DOI: 10.5698/1535-7597.17.6.363
|View full text |Cite
|
Sign up to set email alerts
|

Searching for Autoimmune Epilepsy: Why, Where, and When?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 9 publications
0
3
0
Order By: Relevance
“…However, one should be wary when interpreting our results concerning the fact that some variables known to influence the white matter status could not be controlled for: patients after hemispherotomy may not necessarily have larger lesions, however, it may be guessed that they have a higher seizure burden (which ultimately lead to the indication for hemispherotomy) and a higher antiepileptic drug load, both thought to lower FA values (Jehi, 2017 ). In the hemispherotomy group, however, comparatively higher FA values have been found.…”
Section: Discussionmentioning
confidence: 99%
“…However, one should be wary when interpreting our results concerning the fact that some variables known to influence the white matter status could not be controlled for: patients after hemispherotomy may not necessarily have larger lesions, however, it may be guessed that they have a higher seizure burden (which ultimately lead to the indication for hemispherotomy) and a higher antiepileptic drug load, both thought to lower FA values (Jehi, 2017 ). In the hemispherotomy group, however, comparatively higher FA values have been found.…”
Section: Discussionmentioning
confidence: 99%
“…Although antibodies serve an important role as a biomarker for autoimmunemediated seizure disorders, in occasional cases, immunity is suspected based on clinical, imaging, and CSF results, but antibodies are absent. 16 In these cases, the possible presence of pathogenic autoantibodies that are not yet detectable by current techniques has been suggested by reports of such patients undergoing successful treatment with rituximab, 17 a medication that prevents differentiation of mature B cells into antibody-producing plasma cells. 18 Seronegative cases such as these provide evidence suggesting a broader role of immunity in clinical epilepsy and highlight the need to identify additional biomarkers to facilitate diagnosis.…”
Section: Pathophysiology and Diagnosismentioning
confidence: 99%
“…It is now understood that antibodies can also be present in cases of epilepsy without other features of autoimmune encephalitis and that such individuals are poorly responsive to conventional antiseizure therapies [2]. As well as cases with known autoantibodies, there are cases that are seronegative on antibody testing but still benefit from immunotherapy [3]. This means there is a risk of refractory epilepsy patients with unrecognized autoimmunity remaining undiagnosed, resulting in a lost opportunity to have beneficial treatment, or the use of unnecessary interventions such as surgery [4].…”
mentioning
confidence: 99%